The Foundation for Financial Journalism (https://ffj-online.org/?s=philidor)
The Southern Investigative Reporting Foundation’s story looking at Valeant Pharmaceuticals’ well-concealed relationship with Philidor Rx Services, struck a nerve.
October 25, 2015 https://ffj-online.org/2015/10/25/the-kings-gambit-accepted-the-annals-of-fraud/Derrick Snowdy is probably as close to a celebrity as Canada’s private investigator community has.
May 12, 2021 https://ffj-online.org/2021/05/12/danny-guy-derrick-snowdy-and-the-strange-wars-of-confused-men/A high-profile research analyst who identifies and bets on troubled companies has acquired an unusual and perhaps unwarranted amount of influence in the brief period of time he’s been in this line of work.
November 4, 2019 https://ffj-online.org/2019/11/04/fraser-perring-chronicles-of-deceit-part-one/BofI Federal Bank’s disclosure practices seem baffling at best if the standard it’s judged by is how well it informs investors about developments that could potentially change the risk profile of their capital.
June 28, 2017 https://ffj-online.org/2017/06/28/bofi-federal-savings-disclosing-little-saying-less/Valeant Pharmaceuticals International, the corporate poster child for price-gouging, tax-inversion and hedge-fund manager wealth destruction quietly severed all ties with J. Michael Pearson, its former chief executive officer and longtime guiding light, in January according to its annual proxy statement filed this morning.
March 23, 2017 https://ffj-online.org/2017/03/23/valeant-the-end-of-the-michael-pearson-era/Valeant Pharmaceuticals is the type of company that tends to make even the simplest things complex.
February 3, 2016 https://ffj-online.org/2016/02/03/valeants-contract-follies/Poland seems a most unlikely place for the next chapter of Valeant Pharmaceuticals’ saga to play out. Weighing in at about 3 percent of sales, the Polish operations are seemingly a modest contributor to Valeant’s fast growing bottom line.
December 1, 2015 https://ffj-online.org/2015/12/01/valeants-eastern-front/On Valeant Pharmaceuticals’ conference call on Nov. 10, embattled chief executive J. Michael Pearson offered several defenses of his company’s internal controls and procedures.
November 11, 2015 https://ffj-online.org/2015/11/11/the-curious-case-of-mr-pearsons-502996-shares/If the name Valeant Pharmaceuticals International doesn’t ring a bell, its business practices should. The Quebec-based drug manufacturer’s policy of implementing regular price increases that often run north of 100 percent has generated plenty of anger. Now a slim legal filing in California federal court is poised to make Valeant’s world rockier still.
October 19, 2015 https://ffj-online.org/2015/10/19/hidden-in-plain-sight-valeants-big-crazy-sort-of-secret-story/